Roots Analysis has announced the addition of “CD-47 Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker.

To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-...

Key Market Insights

Over 75 CD-47 drug candidates are under various phases of development
52% of the pipeline candidates are currently in preclinical and discovery stages, while more than 48% therapies are being evaluated in clinical stages with most candidates being in early clinical stages (41.6%); 3.9% and 2.6% of clinical candidates being evaluated in phase II and phase III respectively.

~50 companies claim to be engaged in the development of CD-47 therapeutics, globally
Since 2015, 13 companies have been established in this domain. Further, around 44% of the industry stakeholders are small companies. In addition, majority (47%) of the CD-47 therapeutics developers are based in North America, primarily in the US.

Several clinical trials evaluating CD-47 targeting therapeutics have been registered worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 34.1%, during the period 2015-2020. Of the total, close to 13% of the studies have already been completed, followed by active trials that are actively recruiting patients (46.7%).

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-...

For additional details, please visit
https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-... or email [email protected]

You may also be interested in the following titles:
1. RAS Targeting Therapies Market, 2021-2031
2. Squamous NSCLC Market, 2021-2031
3. Peptide Therapeutics Market, 2021-2031

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/